John Mei is an associate in Goodwin’s Business Law Department and a member of its nationally recognized Technology and Life Sciences group. Mr. Mei represents issuers and underwriters in capital markets transactions, primarily in the life sciences and biotechnology industry, including in initial public offerings, follow-on offerings, at-the-market offerings and convertible and investment-grade debt offerings. Mr. Mei also represents public and private companies in securities law, corporate governance and general corporate matters, including SEC reporting, Nasdaq/NYSE compliance and preparation of board and committee materials.

Mr. Mei also has experience representing buyers, sellers and financial advisors in public and private mergers, acquisitions, divestitures and joint ventures and representing borrowers and lenders in finance transactions, including secured and unsecured credit facilities and royalty monetizations.

Prior to joining Goodwin in 2019, Mr. Mei was an associate at Covington & Burling LLP in New York.

Mr. Mei is admitted to practice in New York only; his application to the Massachusetts bar is pending. He is working under the supervision of the partners at Goodwin.

Areas of Practice
Domaines D’Expertise





Mr. Mei’s recent representations include:

  • CRISPR Therapeutics AG, a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform, in its $517.5 million and $315.2 million follow-on public offerings.
  • argenx SE, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, in its $862.5 million global offering.
  • Axcella Health Inc., a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, in its $60.1 million follow-on public offering and $35 million at-the-market offering.
  • Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurological disorders, in its $35.1 million follow-on public offering.
  • Karyopharm Therapeutics Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases, in its up to $150 million royalty agreement with affiliates of HealthCare Royalty Partners.
  • Repligen Corporation, a bioprocessing company focused on products used to manufacture and purify biologic drugs, in concurrent underwritten public offerings of common stock and convertible senior notes that, together, account for $425.6 million in gross proceeds.
  • Amarin Corporation plc, a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, in a $460 million underwritten public offering of American depositary shares.
  • Leading global life sciences, diagnostics and applied chemical company in multiple investment-grade notes offerings totaling $1.0 billion.
  • Clinical-stage immuno-oncology company in SEC reporting, corporate governance matters and multiple public offerings totaling over $250 million.*
  • Fully integrated biopharmaceutical company focused on autoimmune, inflammatory and fibrotic diseases in SEC reporting, corporate governance matters and an at-the-market offering.*
  • Underwriters in the $67 million initial public offering, two follow-on offerings (totaling over $230 million) and an at-the-market offering by an Israeli clinical-stage urologic oncology company.*
  • Underwriters in three follow-on offerings (totaling over $90 million) and an at-the-market offering by a Dutch clinical-stage immuno-oncology company.*
  • Global animal health company in multiple investment-grade notes offerings totaling over $4.0 billion.*

* Denotes experience prior to joining Goodwin


Mr. Mei was named to The Best Lawyers in America 2021: Ones to Watch.

In The News









J.D., 2014
New York University Law School
B.A., 2011
Dartmouth College



New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique